Capacidad antioxidante de subproductos de semillas de amaranto (Amaranthus hypochondriacus)

Se evaluó la capacidad antioxidante (CA) en subproductos de semillas de amaranto (Amaranthus hypochondriacus) de dos parcelas de cultivo, en función de tres métodos de extracción y dos disolventes, a tres concentraciones diferentes. En una primera etapa, se evaluó el efecto del método de extracción (homogeneización, ultrasonido de baja frecuencia y la combinación homogeneización-ultrasonido) y del disolvente de extracción (metanol o etanol, al 100%); en una segunda etapa, se evaluó el efecto de la concentración del disolvente de extracción (100%, 70% o 50%). La CA se determinó por inhibición del radical DPPH▪, expresándola en mg Equivalentes de Trolox (ET)/g materia seca; los compuestos fenólicos totales (FT) se determinaron mediante el ensayo de Folin–Ciocalteu, expresándolos como Equivalentes de Ácido Gálico (EAG)/g materia seca. Los compuestos antioxidantes se identificaron mediante cromatografía de gases acoplada a espectrometría de masas. Para la CA, no existe diferencia significativa (p>0,05) entre los métodos de extracción estudiados, mientras que si la hay (p<0,05) entre disolventes (3,39 y 1,28 mg ET/g materia seca, con metanol y etanol, respectivamente). Para FT, no hay diferencia significativa (p>0,05) entre disolventes al usarlos diluidos, sólo al emplearlos al 100%; mientras que para CA sí hay efecto de la concentración del disolvente, obteniendo mayores valores de CA al utilizar los disolventes al 50% (21,34 y 21,82 mg ET/g materia seca, con metanol y etanol, respectivamente). El análisis cualitativo de los extractos mostró la presencia de escualeno y 2,5-bis (1,1-dimetiletil) fenol como los principales compuestos con capacidad antioxidante.The antioxidant capacity (CA) of byproducts from amaranth (Amaranthus hypochondriacus) seeds from two harvest parcels as a function of three extraction methods and two solvents was evaluated. On a first stage the effect of extraction method (homogenization, low frequency ultrasound, or the combination homogenization-ultrasound) and extraction solvent (methanol or ethanol, 100%) were evaluated; on a second stage, the effect of extraction solvent concentration (100%, 70%, or 50%) was evaluated. CA was determined by DPPH▪ inhibition, which was expressed as mg Equivalents of Trolox (ET)/g dry matter (DM). Total Phenolic compounds (FT) were determined by means of the Folin–Ciocalteu assay and expressed as Equivalents of Gallic Acid (EGA)/g DM. Antioxidant compounds were identified by gas chromatography coupled to mass spectrometry. For CA, there was not significant difference (p>0,05) among extraction methods, but there was significant difference (p<0,05) between solvents (3,39 and 1,28 mg ET/g DM, with methanol and ethanol, respectively). For FT, there was not significant difference (p>0,05) between solvents when they were diluted, but a significant difference (p<0,05) was observed when they were used at 100%. For CA, there was a significant (p<0,05) effect of solvent concentration, both studied solvents at 50% provided the best results (21,34 and 21,82 mg ET/g DM with methanol and ethanol, respectively). The qualitative analysis of the extracts exhibited the presence of squalene and 2,5-bis (1,1-dimethylethyl) phenol as the major compounds with antioxidant capacity

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN